With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Headline: The addition of enzalutamide to ADT for metastatic castrate-sensitive prostate cancer (mCSPC) prolongs survival over other first-generation androgen receptor (AR)-blockers. The ENZAMET trial randomized over 1100 men with mCSPC on ADT to a first-gen AR-blocker (e.g., bicalutamide, nilutamide, or flutamide) versus the newer AR-blocker enzalutamide. Since docetaxel was coming on the scene, it was allowed in a non-randomized fashion per physician preference. As predicted, overall survival at 3 years was significantly prolonged in the enzalutamide arm from 72 → 79%, which held true across low and high-volume disease. On the other hand, there was no benefit with enzalutamide among those receiving early docetaxel. TBL: If you weren’t confused enough on which systemic therapy to offer first for mCSPC, you can now add enzalutamide to the mix. | Davis, N Engl J Med 2019